Paying for Cures research, recommendations, and tools
The FoCUS consortium has been working since 2016 to identify challenges and design solutions for financing innovative cell and gene therapies, involving the perspectives of diverse system stakeholders.
Paying for Cures Toolkit
FoCUS Consortium research, findings, and interactive worksheets, organized to help you explore Precision Financing Strategies for your organization.
Precision Financing Strategies
This comprehensive white paper lays out the practices and tools that can help make durable therapies sustainable by the healthcare system.
Six suggestions where we can evolve public policy to make the US healthcare financing and reimbursement system ready for innovative therapies
Emerging market solutions for financing and reimbursement of durable cell and gene therapies
Warranty Model: A potential precision financing solution for durable cell and gene therapies
Tracking the CAR-T revolution:
Analysis of clinical trials of CAR-T and TCR therapies for the treatment of cancer
Payer Perspectives on Financing and Reimbursement of One-time High-cost Durable Treatments
Precision Financing Solutions for Durable / Potentially Curative Therapies
Designing financial solutions to ensure affordable access to cures
How can self-insured employers prepare for the portfolio impact of high-cost gene therapies coming to market?
Payer perspectives on outcomes tracking for value-based payment arrangements
The resource navigation challenges for patients and caregivers
Updated projection of US durable cell and gene therapies product-indication approvals
Federal Communication Guidelines
Financing Challenges for Solid-Tumor T-Cell Therapies
Pediatric Gene Therapy Launches
Patient-Caregiver Financial Themes
Clinical trials and investment trends for novel CAR-T and TCR therapies
Model Contracts for Innovative Oncology Therapies
Role of COE networks in curative cellular oncology therapies
Stop-Loss Insurance or Reinsurance for Multiyear Contracts
Impact of Patient Mobility on Annuity/Performance-Based Contracting
Orphan Reinsurer Benefit Managers (ORBMs)
Impact of Actuarial Risk on Health Plans
Designing Precision Financing for Cures
Payer Segmentation for Precision Financing
Quinn, C., Ciarametaro, M., Sils, B., Phares, S., & Trusheim, M. (2023). Medicaid best price reforms to enable innovative payment models for cell and gene therapies. Expert Review of Pharmacoeconomics & Outcomes Research, 23(2), 191–203.
Young, C. M., Trusheim, M., & Quinn, C. (2022). Data for modelling US projections of product approvals, patients treated, and product revenues for durable cell and gene therapies. Data in Brief, 41, 107891.
C. Young; C. Quinn; M. Trusheim. Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues. Drug Discovery Today (2021). DOI: 10.1016/j.drudis.2021.09.001
Ivica NA, Young CM. Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020). Healthcare. 2021; 9(8):1062.
J.F. Barlow; M.W. Courtney; M. Trusheim. Payer Perspectives on Gene Therapy Reimbursement. Pharmaceutical Executive, 04/2020
J.F. Barlow; M.W. Courtney; M. Trusheim. Payer Perspectives on Reimbursement of One-Time High-Cost Durable Therapies. Pharmaceutical Executive, 01/09/2020
J.F. Barlow; M. Yang; R. Teagarden. Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies? Value in Health, 06/2019, 10.1016/j.jval.2018.12.004
J. Barlow; R. Teagarden; M. Trusheim. Precision Financing of Durable, Potentially Curative Therapies. Pharmaceutical Executive, 01/2019
M.R. Trusheim; W.M. Cassidy; P.B. Bach. Alternative State-Level Financing for Hepatitis C Treatment—The "Netflix Model" JAMA, 10/29/2018, 10.1001
D. Han; D.S. Mytelka; G.L. Warren; M. Ciarametaro; M. Trusheim. Improving Management of Gene and Cell Therapies: The Orphan Reinsurer and Benefit Manager (ORBM). PharmaExec.com, 2018
M.R. Trusheim; A.A. Shrier; Z. Antonijevic; R.A. Beckman; R.K. Campbell; C. Chen; K.T. Flaherty; J. Loewy; D. Lacombe; S. Madhavan; H.P. Selker; L.J. Esserman. PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms. Clinical Pharmacology & Therapeutics, 2016, 10.1002/cpt.514
R. Teagarden; T.F. Unger; G. Hirsch. Access and availability of orphan drugs in the United States: advances or cruel hoaxes? Expert Opinion on Orphan Drugs, 2014, 10.1517/21678707.2014.947265
We want to know what works for you, and what doesn't. Please share your thoughts with us!
Subscribe to news
Join our mailing list to keep up to date on Paying for Cures news and events.